Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 1Phase 1 1

Status

Recruiting 6Unknown 5Completed 4Active not recruiting 4Terminated 3Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 26Lymphoid 8Head & Neck 6Thoracic 5Other solid neoplasm 5Breast 3Tumor-Agnostic 2Dermatologic 2Sarcoma 1Gynecologic 1Genitourinary 1

Conditions

Advanced Solid Tumor 3Solid Tumor 1DMMR Colorectal Cancer 1

Interventions

Injections 17Cisplatin 15Carboplatin 15Oxaliplatin 11Gemcitabine 11pembrolizumab 8Capecitabine 8toripalimab 7Paclitaxel 7Etoposide 7Cyclophosphamide 7Pemetrexed 6Irinotecan 6Drug Therapy 6spartalizumab 5fludarabine 5camrelizumab 5Vincristine 5Radiotherapy 5Leucovorin 5tislelizumab 4apatinib 4anlotinib 4Interleukin-2 4Immune Checkpoint Inhibitors 4Granulocyte-Macrophage Colony-Stimulating Factor 4Fluorouracil 4Docetaxel 4Bevacizumab 4tremelimumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Unknown × spartalizumab × Other solid neoplasm × Clear all
NCT04301557 2024-04-23

PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer

Sun Yat-sen University

Phase 2 Unknown
25 enrolled
GastrointestinalOther solid neoplasm

DMMR Colorectal Cancer

NCT03704246 2021-03-04

Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors

Taizhou Hanzhong biomedical co. LTD

Phase 2 Unknown
123 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT04478461 2020-11-13

Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 1 Unknown
21 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT04569916 2020-09-30

Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Unknown
30 enrolled
Other solid neoplasm

Solid Tumor

NCT03975036 2019-06-05

Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody

Henan Cancer Hospital

Phase 2/3 Unknown
100 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡